Project title: Phase II clinical trial on the use of a humanized CART directed against BCMA (ARI0002h) in patients with multiple myeloma relapsed/refractory to proteasome inhibitors, immunomodulators and anti-CD38 antibodies (ICI19/00025)
Financing agency: Carlos III Health Institute
Start and end date: 01/01/2020 – 31/12/2023